View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvr...

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Keple...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité de la société Inventiva concl...

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique ("NASH") et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de...

Solvay SA: 1 director

A director at Solvay SA bought 30,042 shares at 27.740EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Wim Hoste
  • Wim Hoste

Solvay Feedback conference call

Below are the key highlights from the conference call. Solvay's 1Q25 uEBITDA dropped 15% to € 230m, in line with the recent profit warning. Solvay reiterated the (recently cut) FY25 underlying EBITDA guidance of € 880-930m (c. -12% at midpoint vs the previous € 1.0-1.05bn range), citing continued soft demand in a context of tariff and geopolitical uncertainty. Solvay had already stated to maintain FCF guidance of c. € 300m (on the back of more prudent capex spending) which however still means th...

Guy Sips
  • Guy Sips

Melexis 2Q25 release confirming its continued momentum in China and Eu...

We updated our model after 2Q25 showed quarter-on-quarter improvement in both sales and margins. Sales reached € 211.6m, outperforming our estimate of € 200.3m and CSS's forecast of €201.9m. Customers continued to reduce their inventories during the quarter, and Melexis successfully fulfilled the resulting uptick in short-term orders. Melexis noted that 2Q25 sales exceeded expectations, driven by sequential growth in China and EMEA. From an application standpoint, strong performances were record...

Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
Stefano Toffano
  • Stefano Toffano
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch